BioPharma Drug Discovery
Eisai and Biogen Announce Approval of LEQEMBI® (Lecanemab) for Alzheimer’s Disease Treatment in Hong Kong
LEQEMBI is now available for patients with mild cognitive impairment (MCI) or mild dementia, collectively referred to as early AD, the population in which ...
July 11, 2024 | News
DP Technology Nominates DPT0416 as Preclinical Candidate for Alzheimer’s Disease Treatment
DP Technology, an "AI for Science" paradigm-driven company, announced the nomination of DPT0416, a novel CNS penetrable small molecule targeting Lp-P...
July 10, 2024 | News
A*STAR and SingHealth Collaborate on SGD$18 Million TISHUMAP Project to Transform Drug Discovery in Asia
A*STAR’s Genome Institute of Singapore (GIS) has secured nearly SGD$18 million to develop an innovative data platform, TISHUMAP1. This platform is se...
July 09, 2024 | News
XPOVIO® Secures NMPA Approval for Treatment of R/R DLBCL in China, Expanding Its Indications
- Following its initial approval for the treatment of relapsed/refractory multiple myeloma (R/R MM), XPOVIO® has now received approval as a monoth...
July 08, 2024 | News
South Korea's Genexine Merges with EPD Biotherapeutics to Enhance PROTAC Technology and Drug Pipeline
Genexine a publicly-listed, clinical-stage Korean biopharmaceutical company committed to the discovery and development of novel biologics for the tre...
July 05, 2024 | News
Eleva's Factor H Receives Orphan Drug Designation from European Commission for Treating C3 Glomerulopathy
Eleva, a pioneer in unlocking difficult-to-produce biologics based on a breakthrough manufacturing platform, announced today that the European Commis...
July 04, 2024 | News
South Korea's PharmAbcine Advances Novel nAMD Treatment PMC-403 to Key Phase 1 Milestones
PharmAbcine, a clinical-stage public company developing next generation therapeutics to treat medical unmet needs, announced today the decision to advance ...
July 02, 2024 | News
European Commission Approves OBGEMSA™ (Vibegron) for Overactive Bladder Treatment by Pierre Fabre Laboratories
The European Commission (EC) has authorized the marketing of OBGEMSA™ (vibegron) by Pierre Fabre Laboratories for the symptomatic treatment of overac...
July 01, 2024 | News
Cytiva Introduces Supor Prime Filters to Enhance High-Concentration Biologic Drug Manufacturing
Global life sciences leader Cytiva is addressing the distinct filtration needs of customers manufacturing high-concentration biologic drugs with its Supor ...
June 28, 2024 | News
South Korea Approves Reimbursement for Antengene's XPOVIO®, Expanding Access to Relapsed/Refractory Multiple Myeloma Treatment
- XPOVIO® is the first XPO1 inhibitor approved for reimbursement by South Korea's National Health Insurance Service (NHIS) for the treat...
June 27, 2024 | News
Simcere Zaiming's Enlituo® Receives NMPA Approval for mCRC Treatment
Simcere Zaiming, an innovative oncology company and a subsidiary of Simcere Pharmaceutical Group (2096.HK), announced that Enlituo® (generic name: cetu...
June 27, 2024 | News
EU Approves HUTCHMED's FRUZAQLA® for Previously Treated Metastatic Colorectal Cancer
— Approval for previously treated metastatic colorectal cancer based on results from positive, global, Phase III FRESCO-2 Trial — — FRUZ...
June 24, 2024 | News
Menarini Expands Partnership with Pharmacosmos to Bring Innovative Iron Deficiency Treatment to Singapore and Malaysia
Menarini Asia-Pacific (Menarini) announced that it has expanded its partnership with Pharmacosmos A/S (Pharmacosmos), to include exclusive rights to ...
June 19, 2024 | News
Ascentage Pharma Secures $1.3 Billion Deal with Takeda for Global Rights to Olverembatinib
Ascentage Pharma has executed an Exclusive Option to License Global Rights to Olverembatinib worldwide other than China and a few other areas. ...
June 17, 2024 | News
Most Read
- Can APAC Biomanufacturing Decarbonise Without Pricing Itself Out?
- The Algorithm on the GMP Floor: AI Promises a Smarter Plant. Regulators Demand the Audit Trail.
- APAC's Peptide-Capacity Gamble
- After the Rush: APAC's mRNA and Vaccine Capacity Hangover
- The Biosimilar Race: Factory to the World — or Stuck in the Copycat Economy?
- The Vein-to-Vein Problem: Can APAC's Cold Chain Carry Advanced Therapies?
- Vectors, Plasmids and the CGT Trap: APAC's Cell and Gene Therapy Ambitions Face an Upstream Bottleneck
- Can APAC Build Radioligand Therapy Before the Atoms Decay?
- The Great Biopharma Reset: 50 Developments That Changed Everything in H1 2026
- Beyond the Trial: Can Real-World Evidence Earn Regulatory Trust in APAC?
- Beyond the Obvious Giant: Where APAC's Clinical Trials Go Next
- The Frontier That Won’t Quite Arrive
Bio Jobs
- Sanofi Turns The Page As Belén Garijo Steps In And Paul Hudson Steps Out
- Global Survey Reveals Nearly 40% of Employees Facing Fertility Challenges Consider Leaving Their Jobs
- BioMed X and AbbVie Begin Global Search for Bold Neuroscience Talent To Decode the Biology of Anhedonia
- Thermo Fisher Expands Bengaluru R&D Centre to Advance Antibody Innovation and Strengthen India’s Life Sciences Ecosystem
- Accord Plasma (Intas Group) Acquires Prothya Biosolutions to Expand Global Plasma Capabilities
- ACG Announces $200 Million Investment to Establish First U.S. Capsule Manufacturing Facility in Atlanta
- AstraZeneca Invests $4.5 Billion to Build Advanced Manufacturing Facility in Virginia, Expanding U.S. Medicine Production
News
